* Atea Pharmaceuticals Inc is expected to show no change in quarterly revenue when it reports results on February 28 for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Atea Pharmaceuticals Inc is for a loss of 50 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $3.00, below its last closing price of $4.20.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.45 -0.48 -0.40 Beat 16.1
Jun. 30 2023 -0.45 -0.47 -0.34 Beat 27.7
Mar. 31 2023 -0.47 -0.48 -0.43 Beat 9.9
Dec. 31 2022 -0.44 -0.45 -0.41 Beat 8.9
Sep. -0.41 -0.44 -0.10 Beat 77.4
30 2022
Jun. 30 2022 -0.53 -0.52 -0.38 Beat 27.4
Mar. 31 2022 -0.56 -0.58 -0.51 Beat 12.4
Dec. 31 2021 -0.01 0.17 1.34 Beat 704
This summary was machine generated February 26 at 22:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments